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Introduction
The risk of recurrent stroke in patients with symp-
tomatic intracranial arterial stenosis (sICAS) 
remains high and is more pronounced in the ter-
ritory of the stenotic artery with stenosis ⩾70% 
and following recent symptoms [Reith et al. 2015; 
Kasner et  al. 2006]. Although percutaneous 
transluminal angioplasty and stenting (PTAS) is 
technically feasible in this patient subgroup, it did 
not meet the expectations in randomized, con-
trolled trial (RCT) settings and was less effective 
than best medical therapy (BMT) [Chimowitz 
and Derdeyn, 2015].
The aim of the present systematic review and 
meta-analysis was to evaluate both the safety and 
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Abstract
Objectives: The cumulative safety and efficacy measures of percutaneous transluminal 
angioplasty and stenting (PTAS) for secondary stroke prevention in patients with symptomatic 
intracranial arterial stenosis (sICAS) have not previously been evaluated using a meta-
analytical approach.
Methods: We conducted a systematic review and random effects meta-analysis of all available 
randomized controlled trials (RCTs) evaluating the safety and efficacy of PTAS (in comparison 
with medical therapy) for sICAS.
Results: Three RCTs (678 total patients) were included in the quantitative analysis. PTAS was 
associated with a higher risk of recurrent ischemic stroke in the territory of qualifying artery 
both within 30 days [risk ratio (RR) = 2.21, 95% confidence interval (CI) 1.10–4.43] and 1 year 
(RR = 1.92, 95% CI 1.10–3.36). PTAS was also related to a higher risk of any ischemic stroke 
within 30 days from the index event (RR = 2.08, 95% CI 1.17–3.71). The risk for intracranial 
hemorrhage was found to be higher in PTAS patients both within 30 days (RR = 10.60,  
95% CI 1.98–56.62) and 1 year (RR = 8.15, 95% CI 1.50–44.34). The composite outcome of any 
stroke or death within 1 year (RR = 2.29, 95% CI 1.13–4.66) and 2 years (RR = 1.52, 95% CI 
1.04–2.21) was higher in PTAS than in medical therapy. PTAS was associated with a higher  
risk of any stroke or death within 2 years in the sICAS subgroup located in posterior circulation 
(RR = 2.37, 95% CI 1.27–4.42).
Conclusions: PTAS is associated with adverse early and long-term outcomes and should not 
be recommended in patients with sICAS. Further research to identify subgroups of patients 
who could also serve as candidates for future interventional trials along with efforts to reduce 
procedure-related complications are needed.
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efficacy of PTAS for sICAS, in comparison with 
BMT, using data from available RCTs.
Methods
This meta-analysis is presented according to the 
Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) guidelines [Liberati 
et al. 2009]. Eligible placebo-controlled RCTs that 
compared the safety and efficacy of PTAS for 
sICAS with BMT were identified by searching 
MEDLINE, SCOPUS and the CENTRAL 
Register of Controlled Trials. The complete search 
algorithm used in the MEDLINE search was: 
(“percutaneous transluminal angioplasty”[All 
Fields] OR (“stents”[MeSH Terms] OR 
“stents”[All Fields] OR “stenting”[All Fields]) OR 
(“stents”[MeSH Terms] OR “stents”[All Fields] 
OR “stent”[All Fields])) AND (intracranial[All 
Fields] AND (“constriction, pathologic”[MeSH 
Terms] OR (“constriction”[All Fields] AND 
“pathologic”[All Fields]) OR “pathologic 
constriction”[All Fields] OR “stenosis”[All 
Fields])) AND ((“stroke”[MeSH Terms] OR 
“stroke”[All Fields]) OR “cerebral ischemia”[All 
Fields]) AND Clinical Trial[ptyp].
We excluded from further analysis all: (1) obser-
vational studies; (2) case series or case reports; 
(3) clinical trials with no randomization proto-
col; and (4) single-arm RCTs. In each eligible 
study we employed the Cochrane Collaboration 
tool to address for biases [Higgins et al. 2011], 
and extracted data regarding the reported events 
of stroke (ischemic or hemorrhagic) and/or death 
at any given timepoint. For each outcome we 
calculated the corresponding risk ratios (RRs) 
for each study protocol, while the pooled RRs 
were estimated using a random-effects model 
(DerSimmonian Laird). We assessed heteroge-
neity between studies with the Cochran Q and I2 
statistics [Khan et  al. 2014; Tsivgoulis et  al. 
2014; Katsanos et al. 2014]. All statistical analy-
ses were conducted using the Review Manager 
(RevMan) Version 5.3 software (Copenhagen: 
The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014).
Results
The literature search returned five potential eligi-
ble studies (Figure 1). After retrieving the full 
texts of the aforementioned studies, we excluded 
two study protocols as they were single-arm [Levy 
et al. 2011] or non-randomized trials [SSYLVIA 
Study Investigators, 2004]. The remaining three 
study protocols, comprising a total of 678 patients 
[mean age 61.4 years, 63% men, 65% with 
ischemic stroke (IS)], were included in both the 
qualitative and quantitative synthesis. The base-
line characteristics of included studies [Chimowitz 
et  al. 2011; Compter et  al. 2015; Zaidat et  al. 
2015] are briefly summarized in Table 1.
Qualitative assessment is presented in Figure 2. 
Even though all three RCTs had open-label 
treatment with blinded end-point evaluation 
(PROBE design) [Chimowitz et  al. 2011; 
Compter et al. 2015; Zaidat et al. 2015], we con-
sidered that the outcome measure was likely not 
influenced by the lack of blinding. However, we 
assessed the risk of performance bias as high in 
two out of three study protocols, since they 
reported that follow up was performed by physi-
cians who were not blinded to the patients’ treat-
ment assignment [Chimowitz et  al. 2011; 
Compter et  al. 2015]. Only one of the studies 
reported solely funding from public sources 
[Compter et al. 2015], while another one reported 
that funding was mainly by public entities and 
academic institutions but also acknowledged 
receiving industry support [Chimowitz et  al. 
2011]. Finally, the risk of bias was considered 
high in the third study, as not only did the trial 
sponsor have a clear conflict of interest in the 
study topic, but also had crucial involvement in 
all study domains (design, conduction, data col-
lection, analysis, interpretation, review of the 
manuscript) [Zaidat et al. 2015].
Overall analyses for reported outcomes are pre-
sented in Table 2. PTAS was associated with 
higher risk of recurrent IS in the territory of quali-
fying artery both within 30 days (RR = 2.21, 95% 
CI 1.10–4.43; Figure 3) and 1 year (RR = 1.92, 
95% CI 1.10–3.36; Figure 4), as well as with the 
risk of any stroke within 30 days (RR = 2.08, 
95% CI 1.17–3.71; Figure 5). The 30-day and 
1-year risk for intracranial hemorrhage was higher 
in PTAS group [RR (30 days) = 10.60, 95% CI 
1.98–56.62, Figure 6; RR (1 year) = 8.15, 
95% CI 1.50–44.34, Figure 7]. The composite 
outcome of any stroke or death within 1 year (RR 
= 2.29, 95% CI 1.13–4.66; Figure 8) and 2 years 
(RR = 1.52, 95% CI 1.04–2.21; Figure 9) was 
higher in PTAS. PTAS was associated with a 
higher risk of any stroke or death within 2 years 
in the sICAS subgroup located in posterior 
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circulation (RR = 2.37, 95% CI 1.27–4.42; 
Figure 10). Finally, PTAS tended to be associ-
ated with a higher risk of IS recurrence in the 
territory of the qualifying artery after 30-days 
(RR = 1.56, 95% CI 0.67–3.67; Figure 11) and 
with disabling or fatal stroke (modified Rankin 
scale score >3) at 1 year (RR = 1.57, 95% CI 
0.86–2.87; Figure 12). Significant heterogeneity 
was not documented in any of the presented anal-
yses with the exception of the composite outcome 
of any stroke or death within 1 year (I2 = 70%, 
p for Cochran Q = 0.04; Figure 8).
Figure 1. PRISMA flow chart presenting the selection of eligible studies.
Table 1. Baseline population characteristics of the included studies.
Study Total 
patients
PTAS 
subgroup
Mean 
age 
(years)
Males HTN DM HLP Smoking CAD IS Posterior 
circulation 
ischemia
Stenosis 
definition
Chimowitz 
et al. [2011]
451 224 (49.7%) 60.2 60.3% 89.6% 46.3% 88.0% 27.3% 23.5% 65.2% 35.5% ⩾70%
Compter 
et al. [2015]
115  57 (49.6%) 65.5 74.0% 67.8% 16.5% 88.7% 28.7% 28.7% 65.2% 100% ⩾50%
Zaidat et al. 
[2015]
112  59 (52.7%) 61.8 65.2% 82.1% 40.2% 54.5% 20.5% 19.6% 62.5% NR ⩾70%
PTAS, percutaneous transluminal angioplasty and stenting; HTN, hypertension; DM, diabetes mellitus; HLP, hyperlipidemia; CAD, coronary artery 
disease; IS, ischemic stroke; NR, not reported.
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Discussion
Our meta-analysis showed that PTAS is associ-
ated with adverse early and long-term outcomes 
including both ischemic and hemorrhagic stroke. 
This association persisted for the sICAS sub-
group located in posterior circulation. Finally, we 
documented no evidence of significant heteroge-
neity in eight out of nine prespecified outcome 
events evaluated in the present meta-analysis.
SAMMPRIS investigators have reported perfora-
tor occlusion as the most common cause of 
periprocedural IS, presumably due to plaque 
debris embolism into small perforator vessels dur-
ing angioplasty or stent deployment [Fiorella 
et al. 2012]. Apart from the procedure-related IS 
both VISSIT and SAMMPRIS trials reported 
that the risk of cerebral ischemia in the territory of 
the stenotic artery remained increased even after 
the 30-day perioperative period, while an unex-
pectedly high risk of intracranial hemorrhage after 
stenting was consistently documented in periop-
erative and follow-up periods [Chimowitz and 
Derdeyn, 2015; Lutsep et al. 2015; Derdeyn et al. 
2013]. More specifically, PTAS was associated 
with a higher risk of periprocedural subarachnoid 
Figure 2. Risk of bias. (A) Summary: review authors’ judgments about each risk of bias item for each included 
study. (B) Graph: review authors’ judgments about each risk of bias item presented as percentages across all 
included studies.
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Table 2. Overall analyses for reported outcomes in the studies included in the meta-analysis.
Outcome Studies (N) RR (95% CI) p value I2 p value for 
Cochran Q
Ischemic stroke in the territory of 
qualifying artery within 30 days
2 2.21 (1.10–4.43) 0.03 0% 0.57
Any ischemic stroke within 30 
days
3 2.08 (1.17–3.71) 0.01 0% 0.72
Ischemic stroke in the territory of 
qualifying artery after 30 days
3 1.56 (0.67–3.67) 0.30 37% 0.20
Ischemic stroke in the territory of 
qualifying artery within 1 year
3 1.92 (1.10–3.36) 0.02 31% 0.24
Intracranial hemorrhage within 
30 days
3 10.60 (1.98–56.62) 0.006 0% 0.79
Intracranial hemorrhage within 
1 year
2 8.15 (1.50–44.34) 0.02 0% 0.71
Any stroke or death within 1 year 3 2.29 (1.13–4.66) 0.02 70% 0.04
Any stroke or death within 2 years 2 1.52 (1.04–2.21) 0.03 0% 0.63
Any stroke or death for sICAS 
located in posterior circulation 
within 2 years
2 2.37 (1.27–4.42) 0.006 0% 0.49
Disabling or fatal stroke* within 
1 year
2 1.57 (0.86–2.87) 0.14 0% 0.71
*Defined as modified Rankin scale score >3.
RR, relative risk; sICAS, symptomatic intracranial arterial stenosis.
Figure 3. Pooled analysis for the outcome: ischemic stroke in the territory of qualifying artery within 30 days.
Figure 4. Pooled analysis for the outcome: ischemic stroke in the territory of qualifying artery within 1 year.
Figure 5. Pooled analysis for the outcome: any ischemic stroke within 30 days.
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hemorrhage (because of vessel perforation) and 
reperfusion intraparenchymal hemorrhage [Reith 
et al. 2015; Chimowitz and Derdeyn, 2015].
Our findings lend support to current AHA recom-
mendations indicating that PTAS should not be 
offered as initial treatment in sICAS patients 
[Kernan et al. 2014]. Further research is required 
to identify patient subgroups with high risk of 
stroke recurrence (e.g. patients with multiple prior 
ischemic events unresponsive to BMT, acute 
stroke patients treated with PTAS during the first 
Figure 6. Pooled analysis for the outcome: intracranial hemorrhage within 30 days.
Figure 7. Pooled analysis for the outcome: intracranial hemorrhage within 1 year.
Figure 8. Pooled analysis for the outcome: composite outcome (any stroke or death) within 1 year.
Figure 9. Pooled analysis for the outcome: composite outcome (any stroke or death) within 2 years.
Figure 10. Pooled analysis for the outcome: composite outcome (any stroke or death) for symptomatic 
intracranial arterial stenosis located in posterior circulation within 2 years.
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month following the index event). In addition, 
efforts to reduce procedure-related complications 
(regional perforator infarction, delayed intra-
parenchymal hemorrhage, wire perforation) need 
to be promoted [Chatterjee and Derdeyn, 2015]. 
The China Angioplasty and Stenting for 
Symptomatic Intracranial Severe Stenosis 
(CASSISS) trial is an ongoing, multicenter RCT 
aiming to redefine the role of PTAS in selected 
patients with sICAS, by overcoming the short-
comings of previous RCTs [Gao et al. 2015].
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